NCT06391710View on ClinicalTrials.gov

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

January 31, 2026

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

HRS9531

subcutaneous

DRUG

Placebo

subcutaneous

Trial Locations (1)

100020

RECRUITING

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY